According to the company, the Hemopurifier is a medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins from the entire circulatory system.
Safety of the Hemopurifier has been demonstrated in multi-site human studies, with robust viral load reductions observed in enrolled hepatitis-C (HCV) infected patients, the company said.
Jim Joyce, Aethlon’s chairman and CEO, said: “Our cytomegalovirus (CMV) research programs will study both the therapeutic and diagnostic potential of our Hemopurifier.
“While CMV represents an exciting new market opportunity, our immediate goals remain the establishment of a GMP manufacturing relationship and the hopeful demonstration that our Hemopurifier is able to reduce viral load in both HCV and HIV infected individuals, which likely would be the first such accomplishment by a single therapeutic candidate.”